Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2019-07-24 Report Publication Anno…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
Report Publication Announcement Classification · 1% confidence The document is a press release dated July 24, 2019, announcing that the management team of Verona Pharma plc will conduct face-to-face meetings at the BTIG Biotechnology Conference 2019 and present at the 2019 Wedbush PacGrow Healthcare Conference. This content details planned investor engagement activities, specifically presentations and meetings at industry conferences, which is characteristic of investor relations communication aimed at updating the market on management visibility and upcoming events. This fits best under Investor Presentation (IP) or a general announcement, but since it is specifically about management presenting at conferences, it aligns closely with the intent of an Investor Presentation or a general update on investor activities. Given the options, it is an announcement about management's investor outreach schedule, which is a form of investor communication. It is not a formal regulatory filing (like 10-K, ER, IR), nor is it a transcript (CT) or a dividend notice (DIV). It is an announcement about management's planned investor engagement, which is often grouped with Investor Presentations (IP) or sometimes Regulatory Filings (RNS) if no better fit exists. Since it details specific conference participation, it is a form of investor outreach material/announcement. However, looking closely at the definitions, 'Investor Presentation' (IP) is for detailed presentations on financials/strategy. This document is an announcement *about* attending conferences, not the presentation itself. It is a general corporate update regarding investor relations activities. Since it doesn't fit the specific financial report types, and it's not a proxy or management change, the most appropriate general category for an announcement about management's investor outreach schedule is Regulatory Filings (RNS) as a catch-all for non-standard corporate announcements, or potentially a very broad interpretation of Investor Presentation (IP). Given the nature of announcing management meetings at conferences, RNS (Regulatory Filings/General Announcement) is the safest fallback, but let's re-evaluate if it fits 'IP'. IP is defined as 'Detailed presentation for investors focusing on financials, strategy, and market position.' This document is an announcement *of* management attendance, not the presentation content itself. Therefore, RNS is the most appropriate fallback for this type of corporate news release that doesn't fit the specific financial or governance categories.
2019-07-24 English
Result of AGM
AGM Information Classification · 1% confidence The document explicitly states 'Result of AGM' and mentions that the company 'held its Annual General Meeting ("AGM") earlier today at which all resolutions were duly passed.' This directly corresponds to the AGM Information category. Although it is a result announcement, the content is focused on the outcome of the AGM itself, making AGM-R the most specific fit over a general RPA or RNS.
2019-07-18 English
AGM Statement
AGM Information Classification · 1% confidence The document is explicitly titled 'AGM Statement' and states that the company 'will hold its Annual General Meeting ("AGM") later today.' It contains a statement from the Chairman intended for shareholders at the AGM. Although it is filed via RNS (RNS Number : 9072F), the primary content and purpose relate directly to the Annual General Meeting materials. Therefore, the most specific classification is AGM Information (AGM-R). The document length is relatively short (4570 chars), but the content is the statement itself, not just an announcement that a presentation will follow, making AGM-R more appropriate than RPA.
2019-07-18 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1494 characters) and begins with an 'RNS Number' (5702F), indicating it is a regulatory news service announcement from the London Stock Exchange. The content discusses a 'Second Price Monitoring Extension' for a security, which is a specific operational notice related to trading halts or volatility controls. This type of miscellaneous, time-sensitive regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified under the general regulatory filing category.
2019-07-15 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1477 characters) and contains an 'RNS Number' and mentions 'London Stock Exchange'. The content explicitly discusses a 'Price Monitoring Extension' and an 'auction call extension' related to trading mechanisms, which is a specific operational announcement rather than a comprehensive financial report (like 10-K or IR) or a standard corporate action (like DIV or CAP). Since it is a regulatory announcement disseminated via RNS that doesn't fit into the more specific categories (like DIRS, MANG, DIV, etc.), the most appropriate classification is the general Regulatory Filings category (RNS).
2019-07-15 English
Second Price Monitoring Extn
Transaction in Own Shares Classification · 1% confidence The document is very short (1494 characters) and contains the header 'RNS Number : 4151E'. It describes a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. This type of immediate, short-form regulatory update that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing, which corresponds to the RNS category, as it is explicitly sourced from RNS and relates to market operations.
2019-07-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.